Publications 2025

Gomes F, Devesa F, Ayuda-Durán P, Aza P, Agote-Arán A, Cavero D, Embarc-Buh A, González A, Bermejo R, Calzada A (2025)
Loss of G1-phase CDK-inhibition biases instability between genomic regions by unevenly reducing activity among replication origins
iScience, 28 (6), 112757
DOI 10.1016/j.isci.2025.112757, PubMed 40546943

Publications 2024

Fuentes-Martín R, Ayuda-Durán P, Hanes R, Gallego-Yerga L, Wolterinck L, Enserink JM, Álvarez R, Peláez R (2024)
Promising anti-proliferative indolic benzenesulfonamides alter mechanisms with sulfonamide nitrogen substituents
Eur J Med Chem, 275, 116617
DOI 10.1016/j.ejmech.2024.116617, PubMed 38959729

Publications 2023

Andersen AN, Brodersen AM, Ayuda-Durán P, Piechaczyk L, Tadele DS, Baken L, Fredriksen J, Stoksflod M, Lenartova A, Fløisand Y, Skånland SS, Enserink JM (2023)
Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling
Cell Rep Methods, 3 (12), 100654
DOI 10.1016/j.crmeth.2023.100654, PubMed 38065095

Ayuda-Durán P, Hermansen JU, Giliberto M, Yin Y, Hanes R, Gordon S, Kuusanmäki H, Brodersen AM, Andersen AN, Taskén K, Wennerberg K, Enserink JM, Skånland SS (2023)
Standardized assays to monitor drug sensitivity in hematologic cancers
Cell Death Discov, 9 (1), 435
DOI 10.1038/s41420-023-01722-5, PubMed 38040674

Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T (2023)
Robust scoring of selective drug responses for patient-tailored therapy selection
Nat Protoc, 19 (1), 60-82
DOI 10.1038/s41596-023-00903-x, PubMed 37996540

Hanes R, Ayuda-Durán P, Rønneberg L, Nakken S, Hovig E, Zucknick M, Enserink JM (2023)
screenwerk: a modular tool for the design and analysis of drug combination screens
Bioinformatics, 39 (1)
DOI 10.1093/bioinformatics/btac840, PubMed 36573326

Tislevoll BS, Hellesøy M, Fagerholt OHE, Gullaksen SE, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele DS, Skavland J, Baliakas P, Hovland R, Andresen V, Seternes OM, Tvedt THA, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT (2023)
Early response evaluation by single cell signaling profiling in acute myeloid leukemia
Nat Commun, 14 (1), 115
DOI 10.1038/s41467-022-35624-4, PubMed 36611026

Tislevoll BS, Hellesøy M, Fagerholt OHE, Gullaksen SE, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele DS, Skavland J, Baliakas P, Hovland R, Andresen V, Seternes OM, Tvedt THA, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT (2023)
Author Correction: Early response evaluation by single cell signaling profiling in acute myeloid leukemia
Nat Commun, 14 (1), 1767
DOI 10.1038/s41467-023-37488-8, PubMed 36997540

Publications 2021

Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021)
Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening
PLoS One, 16 (3), e0248140
DOI 10.1371/journal.pone.0248140, PubMed 33690666

Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS (2021)
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
Mol Oncol, 16 (5), 1153-1170
DOI 10.1002/1878-0261.13153, PubMed 34861096

Publications 2020

Omsland M, Andresen V, Gullaksen SE, Ayuda-Durán P, Popa M, Hovland R, Brendehaug A, Enserink J, McCormack E, Gjertsen BT (2020)
Tyrosine kinase inhibitors and interferon-α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines
FASEB J, 34 (3), 3773-3791
DOI 10.1096/fj.201802061RR, PubMed 31945226

Tadele DS, Robertson J, Crispin R, Herrera MC, Chlubnová M, Piechaczyk L, Ayuda-Durán P, Singh SK, Gedde-Dahl T, Fløisand Y, Skavland J, Wesche J, Gjertsen BT, Enserink JM (2020)
A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation
J Biol Chem, 296, 100179
DOI 10.1074/jbc.RA120.015285, PubMed 33303632

Publications 2019

Zhang B, Ayuda-Durán P, Piechaczyk L, Fløisand Y, Safont MM, Karlsen IT, Fandalyuk Z, Tadele D, van Mierlo P, Rowe AD, Robertson JM, Gjertsen BT, McCormack E, Enserink JM (2019)
GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells
Haematologica, 104 (5), e229
DOI 10.3324/haematol.2019.220533, PubMed 31040234

Publications 2017

Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K (2017)
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
Oncotarget, 8 (14), 22606-22615
DOI 10.18632/oncotarget.15146, PubMed 28186983

Publications 2014

Ayuda-Durán P, Devesa F, Gomes F, Sequeira-Mendes J, Avila-Zarza C, Gómez M, Calzada A (2014)
The CDK regulators Cdh1 and Sic1 promote efficient usage of DNA replication origins to prevent chromosomal instability at a chromosome arm
Nucleic Acids Res, 42 (11), 7057-68
DOI 10.1093/nar/gku313, PubMed 24753426